September 29, 2016 3:14 PM ET

Healthcare Equipment and Supplies

Company Overview of BAROnova, Inc.

Company Overview

BAROnova, Inc., a clinical-stage medical-device company, engages in developing non-surgical non-pharmacologic devices to induce weight loss. It develops TransPyloric Shuttle, a weight-loss system that focuses on potentially slowing a person's gastric emptying, which is a known mechanism of action for weight loss. The company was formerly known as Polymorfix, Inc. BAROnova, Inc. was founded in 2006 and is based in Goleta, California.

281 Magnolia Avenue

Suite 300

Goleta, CA 93117

United States

Founded in 2006





Key Executives for BAROnova, Inc.

Chief Executive Officer, President and Director
Age: 51
Founder and Strategic Advisor
Vice President of Research and Development
Director of Quality Assurance
Vice President of Clinical Affairs
Age: 52
Compensation as of Fiscal Year 2016.

BAROnova, Inc. Key Developments

Square 1 Bank Announces Credit Facility to BAROnova, Inc

Square 1 Bank announced that it has provided a $7.5 million credit facility to new client BAROnova, Inc. Proceeds from the credit facility will supplement the company’s recently raised Series D equity round to support continued growth and strategic initiatives.

BAROnova, Inc. Announces Executive Changes

BAROnova, Inc. announced the appointment of David S. Thrower as President and Chief Executive Officer. Mr. Thrower will also become a member of the company's Board of Directors. BAROnova's founding CEO, Hugh Narciso, will continue to serve the company as a strategic advisor. Mr. Thrower's career in the medical device industry has spanned over two decades. He most recently served as CEO of Asante Solutions. Prior to that, he was CEO of InSound Medical, Inc.

BAROnova, Inc. Announces Enrollment of the First Four Patients in its ENDObesity® II Study

BAROnova, Inc. announced the enrollment of the first four patients in its ENDObesity® II Study, a twelve-month multicenter pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle® (TPS®) to treat obesity. The ENDObesity II Study is projected to enroll 270 patients at up to 12 sites in the United States. The results from this study are expected to support an FDA application for TPS approval and subsequent domestic commercialization of the device.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Private Placement
November 23, 2015

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BAROnova, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at